Guess The Pick and Win $1000 CASH

Stock News All Day retweeted

Daily Stock Deals @TOP10STOCKS 

 #TRADERS STEP UP! #GUESS the PICK you could WIN $1000 $CASH JOIN your FELLOW TRADERS NOW! http://contest.dailystockdeals.com/ 

0 replies 22 retweets 14 favorites

show your penny stock knowledge, show your skill, guess to win $1000 cash from Daily Stock Deals now

OTC Stock iQ retweeted

Daily Stock Deals @TOP10STOCKS 

@BIGMONEYMIKE6 #TEAMFAM Members #TRADERS show your SKILL #GUESSMIKESPICK & #WIN $1000 $CASH from @DailyStockDeals http://contest.dailystockdeals.com/ 

0 replies 16 retweets 1 favorite

See our 3 Pikcs up double Digits AGAIN! it's insane @DailyStockDeals baby! Discover New Ways to Make More Money with Daily Stock Deals!

Stock News All Day retweeted

Daily Stock Deals @TOP10STOCKS 

Our 3 #Alerts from Friday Kicking ASS! $SYNC $SYRX $LIVE Discover New Ways 2 Make More #MONEY with @DailyStockDeals http://www.dailystockdeals.com/ 

 26 retweets 3 favorites

Discover More Way to Make Money in the Market, There are more ways to make money than you think, find out @DAILYSTOCKEALS

Stock News All Day retweeted

Daily Stock Deals @TOP10STOCKS 

3 Alerts from Midday: $SYNC UP 22% $SYRX 16% $LIVE JUMPED 26% Discover MORE Ways 2 Make MONEY with @Dailystockdeals @TOP10STOCKS @TOP10picks

0 replies 23 retweets 

Incredible! $1000 in cold hard CASH, WIN $$$$ just Guess the Pick from @DailyStockDeals www.DailyStockDeals.com

@BIGMONEYMIKE6 #TEAMFAM Members The COUNTDOWN to TURN $500 INTO $5000 is ON! NOW You could ALSO WIN $1000 $CASH $$$$ http://contest.dailystockdeals.com/ 

0 replies 25 retweets 22 favorites

IF you can Guess You could WIN $1000 Cash, Guess the Pick and Win $1000 Cash

@BIGMONEYMIKE6 #TEAMFAMAll All you NEED is JUST #GuessMikesPick FOR a chance to WIN $1000 $CASH ENTER NOW! click http://contest.dailystockdeals.com

Santa Lands on Wall Street, DOW hits 18000, The Gravy Train Rumbles on with 1% of Americans on Board, Pause & Think of the Needy & Poor

Daily Stock Deals retweeted

Daily Stock Deals @Dailystockdeals  ·  30m 30 minutes ago

$DOW 18000 #Santa Lands on #WallStreet The #GravyTrain with 1% on-board Rumbles Pause! Think of Poor & #Needy #Donate http://DailyStockDeals.com 

27 retweets 1 favorite

Cruz and Rubio are the BIGGEST Losers in New Cuban Policy, How Obama Cut Two Cubans to Size, Bush & Paul camps euphoric and thankful

Daily Stock Deals retweeted

Saleem Hijazy @saleemhijazy  ·  17h 17 hours ago

How #Obama Cut two Cubans to size! 2 Cuban-American-Senators @SenTedCruz & @SenMarcoRubio suffered Great Blow, Presidential Ambitions vanish

0 replies 14 retweets 0 favorites

Gold up Sharply as Stocks tank, DOW Down more than 100 points learn more at www.DailyStockDeals.com

Top 10 Winners! retweeted

Daily Stock Deals @TOP10STOCKS 

#Urgent Gold Rockets, Stocks Tank! Watch Gold Stock! brought to you by http://www.dailystockdeals.com/  @TOP10STOCKS #GOLD #Silver #stocks @TOP10picks

Aethlon Medical, AEMD, Profile, Summary

Aethlon Medical, AEMD, Profile, Summary

Aethlon Medical (AEMD) is developing innovative medical devices to address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Aethlon’s ADAPT™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as HIV and Hepatitis C.

HER2 Protein and Breast Cancer

Breast cancer is the most common form of cancer in women, accounting for 20% of cancer deaths with approximately 180,000 women diagnosed annually in the United States (Merrill, R. M., and A. Sloan. 2011. Risk-adjusted female breast cancer incidence rates in the United States. Cancer Epidemiol.). Over-expression of the human epidermal growth factor receptor 2 (HER2; ErbB2) gene occurs in approximately 25% of breast cancers and has been linked to poor prognosis (Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182). HER2 is a receptor tyrosine kinase, member of the EGF receptor family, which possesses proliferative and anti-apoptotic activities.

The standard of treatment for women diagnosed with HER2+ breast cancer includes the humanized monoclonal antibody trastuzumab (marketed as Herceptin®) directed against the extracellular domain of HER2. Trastuzumab binding to HER2 mediates direct growthinhibition of tumor cells and induces antibody-dependent cell cytotoxicity (ADCC), a major anti-cancer mechanism by which natural killer (NK) cells lyse antibody-coated tumor cells (Nahta, R., D. Yu, M. C. Hung, G. N. Hortobagyi, and F. J. Esteva. 2006. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-280).

In patients with metastatic breast cancer undergoing chemotherapy, treatment with trastuzumab augments overall response rates and increases median survival time by 25% (Baselga, J. 2001. Clinical trials of Herceptin® (trastuzumab). Eur J Cancer 37 Suppl 1:18-24). However, response rates to trastuzumab range from 12% to 34% with median duration of 9 months due to development of resistance. Despite co-treatment with other HER2 targeting therapies (e.g. the tyrosine kinase inhibitor lapatinib) and chemotherapy, patients with metastatic breast cancer experience a limited duration of benefit; therefore, novel treatment strategies that act synergistically or overcome drug resistance are urgently needed (Sachdev, J. C., and M. Jahanzeb. 2011. Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer.

The Evolution of Therapeutic Filtration to Improve Hepatitis-C Virus (HCV) Treatment Outcomes

Therapeutic filtration of HCV from the entire circulatory system with a medical device has been clinically demonstrated to improve treatment outcomes when administered at the outset of standard of care (SOC) drug therapy. This summary overview, which includes an introduction to the Aethlon Hemopurifier®, is for informational purposes only.

About HCV Infection

The U.S. National Institutes of Health (NIH) reports an estimated 180 million people worldwide are afflicted with chronic HCV infection. Of people infected, 55 to 85% of will develop chronic infection, and 75% of those will develop chronic liver disease. Standard of care (SOC) drug therapy is represented by a two drug combination of interferon and ribavirin. The primary goal of SOC drug therapy is the achievement of a sustained virologic response (SVR), defined as undetectable viral load six months after completion of SOC drug therapy. According to the NIH, 15-25% of HCV infected patients will recover

completely.

SOC Drug Therapy Outcomes

•The largest study of HCV infected individuals pursuing 48-week SOC drug

therapy was a study of 4,469 genotype 1 patients published by McHutchison in The New England Journal of Medicine in August of 2009.

•31% (1,399 of 4,469) of patients screened for participation were excluded from the study.

•54% (1,654 of 3,070) of treated patients completed the SOC treatment regimen.

•39.6% (1,215 of 3,070) of treated patients who completed SOC therapy

achieved a SVR.

•27% (1,215 of 4,469) of the total patients screened for study participation

achieved a SVR.

•No data recorded for patients who may have relapsed after achieving a SVR.

The Hemopurifier®

The first medical device to selectively remove HCV and related immunosuppressive proteins from circulation. A Study of the Hemopurifier® + SOC Drug Therapy is Now Underway

•Patient enrollment has been initiated at the Medanta Medicity Institute in India - www.medanta.org

•Additional details can be accessed from the Clinical Trials Registry - India (CTRI) link: http://ctri.nic.in/clinicaltrials/index.jsp

•Up to 30 patients / up to 6 treatments in first 3 days of SOC

•Early clinical endpoints include:

•Immediate Virologic Response (IVR)

•Rapid Virologic Response (RVR)

•Early Virologic Response (EVR)

The Hemopurifier® Other Selected Quick Facts

•70 human treatment experiences administered to date

•An Investigation Device Exemption (IDE) to initiate U.S. studies has been filed with FDA

•Substantial viral load reductions have also been observed in a human HIV study performed in the absence of antiviral drugs

•GMP manufacturing has been established in an FDA approved facility

•The Hemopurifier® has proven broad-spectrum capabilities against viral bioterror and pandemic threats

•The device has been discovered to capture tumor-secreted exosomes known to suppress the immune system of cancer patients

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] OxBridgeResearch.com

ALS, Hepatitis C, Traumatic Brain Injury, Blood Sepsis,breast cancer,HIV,HPV,HCV,SOC, dialysis,DOD,UNT,USPTO, NFL,SOCCOR,MILITARY,COMBAT MISSIONS,PTSD, Ebola

Discover suing VISA over Debit Cards,VISA Sued by Discover!

(Reuters) - Discover Financial Services Inc sued Visa Inc on Tuesday, alleging the world's largest cards company has been using anti-competitive practices in its debit card business, and sought compensation for lost profit, court documents showed.
Discover, through its Pulse Network LLC unit, alleges that "in order to maintain its monopoly, Visa has undertaken a series of illegal actions that undermine competition – harming rival debit networks, merchants, acquirers, card issuers, and consumers."
Representatives at Visa could not immediately be reached for comment outside regular business hours.
Pulse requires its debit cardholders to authorize transactions with a personal identification number (PIN). Most Visa transactions use customer signature.
The lawsuit alleges that "Visa has a long history of making sure that PIN debit does not predominate, including undertaking illegal behavior to fend off competitive threats to its debit network services monopoly."
In the petition, Discover said that Visa is offering economic incentives to merchants to choose the Visa network for transactions.
Discover is challenging a Visa rule that requires financial issuers of Visa signature debit cards to also include Visa's PIN services instead of allowing other PIN networks like Pulse to compete for that business.
The case is Pulse Network LLC v. Visa Inc in the U.S. District Court of Southern District of Texas, Houston Division. Case: 4:14-cv-03391.
(Reporting by Supriya Kurane in Bangalore; Editing by Gopakumar Warrier)



Courtesy: Reuters, published on 11/29/2014 by:
Daily Stock Deals OxBridge Research OTC Stock Wire






VISA,Master Card, Mastercards, Discover, Credit Cards, Debit Cards, Pinless cards, credit card fraud, anti-competitive credit cards, low interest credit cards, low interest cards, interest free, no interest, debit cards, bank cards, store cards.

OxBridge Research Publishes a Comprehensive Research Report on Premier Biomedical. cures for Cancer, Traumatic Brain Injury, Alzheimer’s, Multiple Sclerosis, ALS and Blood Sepsis , collectively over a $700 billion market opportunity.

Company targets Traumatic Brain Injury, ALS, Blood Sepsis and other debilitating diseases affecting millions of Americans

EL PASO, Texas--(BUSINESS WIRE)--
Premier Biomedical, Inc. (OTCBB: “BIEI”) a biopharmaceutical company focused on developing and commercializing innovative treatment therapies for cancer, traumatic brain injury, Alzheimer’s disease, and other afflictions announced today that the investment research company, OxBridge Research, has concluded and published its in-depth study of Premier Biomedical, Inc.
The analyst noted in his report that in addition to the company developing cures for “ Cancer, Traumatic Brain Injury, Alzheimer’s, Multiple Sclerosis, ALS and Blood Sepsis – collectively over a $700 billion market opportunity”, the company has established two outstanding research partnerships with the University of Texas, El Paso (UTEP) and the Department of Defense, and is making preparations to initiate two clinical trials (a trial for Feldetrex and a trial of the Sequential Dialysis Technique).
The complete 28 page report is now available for download from the company's website (http://www.premierbiomedical.com/oxbridge-research-investment-summary/) as well as from OxBridge Research’s site, www.oxbridgeresearch.com
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, in collaboration with the University of Texas at El Paso and US Department of Defense, initially targeting the treatment of Alzheimer's disease, Traumatic Brain Injury, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedical
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Forward-looking statements:- The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements, including those described in the Company's Financial Statements, Management Discussion and Analysis and Material Change Reports filed with the with the United States Securities and Exchange Commission and available at www.sec.gov.
This profile/research report/email letter/blog/posting in forums/social-media/t/f does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities of the Company may or may not have been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. We do not accept responsibility for the adequacy or accuracy of this release.
Disclosure/Disclaimer:- OxBridge Research and its affiliates/partners publish sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by OxBridge and/or its affiliates/partners. OxBridge Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment of up to five thousand dollars in compensation from the company/a third party/shareholder. We receive compensation from companies for providing various IR services, including publication, advertisement, and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer; if you need assistance contact Editor@OxBridgeResearch.com

Contact:

Premier Biomedical, Inc.
W. Hartman, 724-633-7033
info@premierbiomedicalinc.com

NFL Fans who care about Traumatic Brain Injury, TBI, Concussions, ICE Bucket Challenge Supporters helping to find cure for ALS see this Press Release by Premier Bio #BIEI

twitnewswire retweeted

Daily Stock Deals @TOP10STOCKS 

#NFL Fans concerned about #Concussion #Braininjury & #IceBucketChallenge Supporters see important #news http://finance.yahoo.com/news/oxbridge-research-publishes-comprehensive-research-150000505.html … … #BIEI

View summary

0 replies 27 retweets 3 favorites

Union Dental, UDHI, Returns to Profitability

UNION DENTAL returns to profitability for 3^rd quarter

Coral Springs, Florida, / November 11, 2014 / Union Dental Holdings, Inc. (OTC PK: UDHI) - http://www.uniondental.com/ir-

a Company that operates and manages a network of dentists throughout the United States for union members announced the financial results for the quarter ending September 30, 2014. In the Consolidated Statement of earnings the Company reported a profit of $174,138 as income from operations on revenues of $918,508 as compared to a loss of $38,118 from operations on revenues of $1,026,161 during the same period in 2013.

Dr. George Green, President and CEO stated: “Our revenues were lower for the quarter as compared to last year but we were profitable as opposed to a loss for the same period last year on higher revenues showing our staff can adjust to the volatile economic conditions our nation faces.”

About Union Dental Holdings, Inc., Direct Dental Services, Inc. and

Union Dental Corp.

Direct Dental Services and Union Dental Corp. are wholly owned subsidiaries. Direct Dental Services provides dentists with “areas of exclusivity” to participate with various unions including the Communications Workers of America (CWA) and the International Brotherhood of Electrical Workers (IBEW), United Association of Plumbers and Pipe Fitters (UA) and The Association of Flight Attendants – Communications Workers of America (AFA-CWA). Direct Dental Services receives annual management fees from the dentists in exchange for practicing in these “areas of exclusivity” where CWA and IBEW members use the dentists’ services. Union Dental manages a dental practice in Coral Springs, Florida.

WEBSITE: www.uniondental.com/ir

"Safe-Harbor" Statement: Under the Private Securities Litigation Reform Act of 1995. This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

CONTACT INFORMATION:

Dr. George D. Green, President - info@uniondentalcorp.com

Premier Biomedical, BIEI, Profile, Summary

 

Premier Biomedical | BIEI | Profile | Summary

Premier Biomedical (BIEI) is a research-based company that has acquired exclusive licenses for patent-pending medications and medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses: ALS, Traumatic Brain Injury, Multiple Sclerosis, Clinical Depression, Alzheimer’s Disease, Blood Sepsis, and Cancer. The company is in the process of developing targeted medicines and procedures and will prove out their superior efficacy in addressing these diseases and others through laboratory, hospital, and actual patient applications. At the anticipated successful conclusion of the clinical trials, contact will be established with the leading worldwide pharmaceutical firms to establish the right to market and distribute Premier Biomedical’s technology products and procedures.

INVESTMENT HIGHLIGHTS

· The Company’s proprietary Sequential Dialysis Technique and patented candidate drug Feldetrex are expected to provide superior efficacy versus existing medications in treating a large number of the most fatal diseases

o Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia, Traumatic Brain Injury, Blood Sepsis, and Cancer

· The Company has established two outstanding research partnerships with the University of Texas, El Paso (UTEP) and the Department of Defense

o Leverage the substantial infrastructure and resourced capacity of these organizations to perform experimentation and to engage in product development in an inexpensive and efficient manner

o Positive results in animal testing for the Sequential Dialysis Technique treatment of cancer

o Initiation of two clinical trials including a trial for Feldetrex and a trial of the Sequential Dialysis Technique

EXECUTIVE SUMMARY

· Premier Biomedical is a research-based company that intends to discover and develop medical treatments targeting the treatment of:  Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia, Traumatic Brain Injury, Blood Sepsis, and Cancer

· The Company’s proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects

o Superior to current treatments which eliminate the presence of most illnesses but often with catastrophic or even fatal side effects

o Targets cancer, Alzheimer’s disease, Multiple Sclerosis, ALS, blood sepsis, and Traumatic Brain Injury – collectively over $700 billion market opportunity

· Developed a proprietary drug candidate Feldetrex as a potential treatment for Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury

o Expected to deliver significant relief to patients, while presenting fewer side effects than other alternate medications

o The Company was recently granted two US patents for this drug candidate

o The annual market size of all proposed market segments for Feldetrex is $16 billion

· The Company has established two outstanding research partnerships with the University of Texas, El Paso (UTEP) and the Department of Defense

o Leverage the substantial infrastructure and resourced capacity of these organizations to perform experimentation and to engage in product development in an inexpensive and efficient manner

o Positive results in animal testing for the Sequential Dialysis Technique treatment of cancer

o Initiation of two clinical trials including a trial for Feldetrex and a trial of the Sequential Dialysis Technique

Sources: The Company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ

Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

If you would like your company featured or want to learn more, please don't hesitate to contact the Editor. editor [@] OTCking.com

Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia, Traumatic Brain Injury, Blood Sepsis,Cancer,sequential dialysis techniques,DOD,UNT,UofT,USPTO, NFL,SOCCOR,MILITARY,COMBAT MISSIONS,PTSD.